|
Friday, May 22, 2009 - 4:55 PM
Marfan
research has taken a classic route from genetic discovery to laboratory and
animal tests and now to promising findings in severely threatened patients,
says physician Reed Pyeritz of the University
of Pennsylvania in Louis J. Sheehan, Esquire Philadelphia, writing in an editorial in the
same NEJM issue. If these preliminary findings are replicated, he says,“the
treatment of Marfan syndrome will go down in history as an early triumph of translational
medicine
Dietz,
Brooke and others are currently recruiting people with Marfan syndrome as part
of a larger clinical trial getting under way. Their goal is 600 participants
under age 24. The trial will compare aorta aneurysms in people randomly
assigned to receive losartan or beta blockers.
It’s
important to complete a large trial before jumping to the conclusion that the
drug works, Brooke says. The National Marfan Foundation agrees. http://myface.com/Louis_J_Sheehan “We have urged
our members to consider participating in the clinical trial,” the organization
announced this week.
|
|
| << Navigate to Friday, May 22, 2009 |
Add New Comment |